# Observational Study on the Use of Akynzeo® in Patients Receiving HEC

> **NCT03649230** · — · COMPLETED · sponsor: **Purdue Pharma, Canada** · enrollment: 207 (actual)

## Conditions studied

- Chemotherapy-Induced Nausea and Vomiting

## Interventions

- **DRUG:** 300mg netupitant/0.5mg palonosetron hydrochloride

## Key facts

- **NCT ID:** NCT03649230
- **Lead sponsor:** Purdue Pharma, Canada
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-03
- **Primary completion:** 2019-12-30
- **Final completion:** 2020-01-30
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2023-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03649230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03649230, "Observational Study on the Use of Akynzeo® in Patients Receiving HEC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03649230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*